Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Jonathan Douxfils and François Mullier.
Jonathan Douxfils
Connection Strength
8.146
François Mullier
  1. Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rational for monitoring immunoglobulin G levels. Haematologica. 2021 08 12.
    View in: PubMed
    Score: 0.961
  2. Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thromb Res. 2021 07; 203:163-171.
    View in: PubMed
    Score: 0.945
  3. Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application. J Thromb Haemost. 2019 08; 17(8):1273-1287.
    View in: PubMed
    Score: 0.825
  4. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018 02; 16(2):209-219.
    View in: PubMed
    Score: 0.748
  5. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect. 2021 Dec; 10(1):1495-1498.
    View in: PubMed
    Score: 0.245
  6. Post-SARS-CoV-2 vaccination specific antibody decrease - Thresholds for determining seroprevalence and seroneutralization differ. J Infect. 2021 10; 83(4):e4-e5.
    View in: PubMed
    Score: 0.241
  7. NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments. Front Pharmacol. 2021; 12:708302.
    View in: PubMed
    Score: 0.240
  8. Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2. Microorganisms. 2021 Jun 21; 9(6).
    View in: PubMed
    Score: 0.238
  9. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2). Clin Microbiol Infect. 2021 Sep; 27(9):1351.e5-1351.e7.
    View in: PubMed
    Score: 0.236
  10. Viscoelastometric Testing to Assess Hemostasis of COVID-19: A Systematic Review. J Clin Med. 2021 Apr 16; 10(8).
    View in: PubMed
    Score: 0.235
  11. Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data. Data Brief. 2020 Dec; 33:106519.
    View in: PubMed
    Score: 0.228
  12. Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance, and their limitations. J Thromb Haemost. 2020 11; 18(11):3121-3124.
    View in: PubMed
    Score: 0.228
  13. Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study. Thromb Res. 2021 01; 197:20-23.
    View in: PubMed
    Score: 0.227
  14. [Management of the thrombotic risk associated with COVID-19: what is the role of the hemostasis laboratory?] Ann Biol Clin (Paris). 2020 10 01; 78(5):471-481.
    View in: PubMed
    Score: 0.226
  15. Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. Thromb J. 2020; 18:17.
    View in: PubMed
    Score: 0.225
  16. Optimal wavelength for the clot waveform analysis: Determination of the best resolution with minimal interference of the reagents. Int J Lab Hematol. 2019 Jun; 41(3):316-324.
    View in: PubMed
    Score: 0.202
  17. Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma. Int J Lab Hematol. 2019 Apr; 41(2):250-261.
    View in: PubMed
    Score: 0.201
  18. Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. Thromb J. 2018; 16:28.
    View in: PubMed
    Score: 0.199
  19. The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation. Thromb Res. 2018 11; 171:160-166.
    View in: PubMed
    Score: 0.197
  20. Reduction of the turn-around time for the measurement of rivaroxaban and apixaban: Assessment of the performance of a rapid centrifugation method. Int J Lab Hematol. 2018 12; 40(6):e105-e108.
    View in: PubMed
    Score: 0.193
  21. Betrixaban: Impact on Routine and Specific Coagulation Assays-A Practical Laboratory Guide. Thromb Haemost. 2018 Jul; 118(7):1203-1214.
    View in: PubMed
    Score: 0.193
  22. Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests. TH Open. 2018 Apr; 2(2):e202-e209.
    View in: PubMed
    Score: 0.193
  23. An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants. Thromb Res. 2017 Sep; 157:29-37.
    View in: PubMed
    Score: 0.181
  24. Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels. Thromb Res. 2017 08; 156:36-38.
    View in: PubMed
    Score: 0.179
  25. Application of a clot-based assay to measure the procoagulant activity of stored allogeneic red blood cell concentrates. Blood Transfus. 2018 02; 16(2):163-172.
    View in: PubMed
    Score: 0.177
  26. BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis? TH Open. 2018 Jan; 2(1):e68-e88.
    View in: PubMed
    Score: 0.047
  27. Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures. Expert Opin Biol Ther. 2017 10; 17(10):1275-1296.
    View in: PubMed
    Score: 0.045
  28. Perioperative management of patients on direct oral anticoagulants. Thromb J. 2017; 15:14.
    View in: PubMed
    Score: 0.045
  29. Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme. Int J Lab Hematol. 2017 Aug; 39(4):402-408.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.